Edition:
United Kingdom

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

7.00USD
5:37pm BST
Change (% chg)

$-0.22 (-3.05%)
Prev Close
$7.22
Open
$7.13
Day's High
$7.13
Day's Low
$6.75
Volume
14,403
Avg. Vol
42,159
52-wk High
$13.05
52-wk Low
$4.78

Select another date:

Thu, May 24 2018

Photo

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

UPDATE 2-Recro Pharma shares plummet after FDA rejects non-opioid pain shot

* FDA says drug's pain-relieving effect did not meet expectations

BRIEF-Recro Pharma Receives Complete Response Letter From FDA

* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

BRIEF-Recro Pharma Reports Q1 Loss Per Share Of $0.65

* Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S

BRIEF-Recro Pharma Announces Receipt Of Issue Notifications For Three New Patents For Iv Meloxicam

* RECRO PHARMA ANNOUNCES RECEIPT OF ISSUE NOTIFICATIONS FOR THREE NEW PATENTS FOR IV MELOXICAM Source text for Eikon: Further company coverage:

Select another date: